Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
8.930
-0.030 (-0.33%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Prothena Corporation plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
Recap: Prothena Corp Q1 Earnings
↗
May 04, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
May 04, 2023
Via
Benzinga
Prothena Corp Earnings Preview
↗
May 03, 2023
Via
Benzinga
Another Sucess In Alzheimer’s Disease
↗
May 03, 2023
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?
Via
Talk Markets
Where Prothena Corp Stands With Analysts
↗
April 24, 2023
Via
Benzinga
The Latest Analyst Ratings for Prothena Corp
↗
April 03, 2023
Via
Benzinga
Earnings Outlook For Prothena Corp
↗
February 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 14, 2023
Via
Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
↗
February 01, 2023
Via
Benzinga
Analyst Expectations for Prothena Corp's Future
↗
December 21, 2022
Via
Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know
↗
December 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
↗
April 24, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
↗
January 27, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Prothena Corp
↗
November 04, 2022
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings:
Via
Benzinga
Recap: Prothena Corp Q3 Earnings
↗
November 03, 2022
Prothena Corp (NASDAQ:PRTA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 23, 2023
↗
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
↗
January 11, 2023
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.
Via
Talk Markets
How To Weather These Choppy Markets
↗
December 22, 2022
Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider...
Via
Talk Markets
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
↗
December 21, 2022
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...
Via
Talk Markets
Why Prothena Shares Are Trading Lower
↗
December 14, 2022
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of...
Via
Benzinga
Why Prothena Shares Are Nosediving During Tuesday's After-Hours Session
↗
December 13, 2022
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by some 8.35% to $57.95 during Tuesday's after-hours session. The company announced that it has commenced an underwritten public...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
December 13, 2022
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
November 22, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
↗
November 14, 2022
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.
Via
Investor's Business Daily
Earnings Preview: Prothena Corp
↗
November 02, 2022
Prothena Corp (NASDAQ:PRTA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Prothena Corp...
Via
Benzinga
As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside
↗
October 28, 2022
In the past month with the Russell 2000 index up roughly 7%, as compared to the S&P 500 index up nearly 4.8%, it is evident that small cap stocks are leading the charge in this bear market rally. The...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
↗
November 04, 2022
Upgrades
Via
Benzinga
Netflix, Biogen And Other Big Gainers From Wednesday
↗
September 29, 2022
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
↗
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
↗
September 28, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.